Cargando…

Belumosudil: First Approval

Belumosudil (REZUROCK(™)) is a Rho-associated coiled-coil-containing protein kinase (ROCK) inhibitor that has been developed by Kadmon Pharmaceuticals for the treatment of chronic graft-versus-host disease (cGVHD) and systemic sclerosis. In July 2021, belumosudil received its first approval in the U...

Descripción completa

Detalles Bibliográficos
Autor principal: Blair, Hannah A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590654/
https://www.ncbi.nlm.nih.gov/pubmed/34463931
http://dx.doi.org/10.1007/s40265-021-01593-z